Smith+Nephew CEO focusing on orthopedic ASC market: 11 things to know about Roland Diggelmann

Alan Condon -   Print  |

Smith+Nephew CEO Roland Diggelmann is approaching his sixth month as head of the medical device company and turning his attention to the growing orthopedic ASC market this year.

Here are 11 things to know about Mr. Diggelmann and his tenure as CEO so far:

1. For the fourth quarter of 2019, Mr. Diggelmann's first quarter as CEO, Smith+Nephew reported $1.4 billion in revenue and $5.1 billion for the full year. Fourth-quarter revenue increased 8.7 percent and full-year revenue rose 4.4 percent.

2. This year, he aims to boost the company's performance and continue its investment in the developing orthopedics segment in ASCs in the U.S.

3. Smith+Nephew's operations have been impacted by the COVID-19 outbreak in China but expects the situation to normalize in the second quarter of 2020. China represented 7 percent of the company's revenue in 2019.

4. Mr. Diggelmann was appointed CEO of Smith+Nephew in November 2019, following in the footsteps of Namal Nawana, who held the position for almost two years.

5. As CEO, he began with a base salary of about $1.4 million. This year, Mr. Diggelmann will be able to earn up to 150 percent of his base salary in a cash incentive plan, as well as having access to Smith+Nephew's annual equity incentive plan and performance share plan awards.

6. The Swiss executive began his 25-plus year career in the medical device industry with AllPro AG, a manufacturer of artificial joints.

7. In 1997, he joined Sulzer Orthopedics, where he rose up the ranks from director of strategic planning and marketing to executive vice president of sales in Europe and Asia Pacific.

8. After Sulzer Orthopedics, Mr. Diggelmann accepted a position at Zimmer — now Zimmer Biomet — where he served as senior vice president of Europe, the Middle East and the African markets.

9. Before joining Smith+Nephew, he operated as CEO of Roche Diagnostics, a company he spent 12 years at. He served as COO for seven years and CEO for three years, according to his LinkedIn profile.

10. Mr. Diggelmann also serves on several company boards, including reproductive genetics company Igenomix, heart screening company HeartForce AG and Accelerate Diagnostics, a diagnostic company for bacterial infections.

11. He holds a bachelor's degree in business administration from the University of Berne in Switzerland.

More articles on devices:
5 orthopedic expansion projects costing $200M+
5 recent telemedicine developments for spine, orthopedics
Dr. Scott Boden: Telemedicine can achieve spine success if 'reimbursement barriers are reduced'

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers